Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly
| Autor: | Giovanna Cannas, Xavier Thomas, J. Fattoum, M. Boukhit |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Blood transfusion Cost effectiveness medicine.medical_treatment Cost-Benefit Analysis Clinical Biochemistry Quality of life Blood product Internal medicine medicine Economic analysis Humans Blood Transfusion Intensive care medicine Aged Retrospective Studies Aged 80 and over business.industry Biochemistry (medical) Myeloid leukemia Hematology Leukemia Myeloid Acute Cohort Cytarabine Female business medicine.drug |
| Zdroj: | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine. 22(5-6) |
| ISSN: | 1953-8022 |
| Popis: | Blood transfusion requirement represents one of the most significant cost driver associated with acute myeloid leukemia (AML). Low-intensity treatments (low-dose cytarabine, hypomethylating agents) have the potential to reduce transfusion dependence, and improve health-related quality of life.We assessed the cost-effectiveness of treatment types regarding blood product transfusions in a cohort of 214 AML patients aged ≥ 70 years.Analyzes did not indicate any significant overall survival (OS) advantage of intensive chemotherapy comparatively to low-intensity treatment. The difference was significant when compared to best supportive care (BSC) (P0.0001). Blood products transfusion cost per patient was 1.3 times lower with low-intensity therapy and 2.7 times lower with BSC than with intensive chemotherapy. Mean transfusion cost per patient according to OS varied from 2.4 to 1.3 times less with low-intensity treatment comparatively to intensive chemotherapy for patients having OS ≤ 13.3 months. Costs varied from 3.5 to 2.6 times less with BSC comparatively to intensive chemotherapy. In contrast, mean transfusion costs were comparable among treatments for patients with OS13.3 months.Low-intensity treatments represent a cost-effective alternative to BSC and require a reduced number of transfused blood products comparatively to intensive chemotherapy, while OS was not significantly different. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect